{
    "organizations": [],
    "uuid": "48ee4e337404faaf97233e40e0540200da2e84f4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-lartruvo-approved-in-canada-for-th/brief-lartruvo-approved-in-canada-for-the-treatment-of-advanced-soft-tissue-sarcoma-in-adults-idUSFWN1PJ10U",
    "ord_in_thread": 0,
    "title": "BRIEF-Lartruvo (Olaratumab) Approved In Canada For The Treatment Of Advanced Soft Tissue Sarcoma In Adults",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 24 (Reuters) - Eli Lilly And Co:\n* LARTRUVO(OLARATUMAB) APPROVED IN CANADA FOR THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA IN ADULTS\n* ELI LILLY CANADA INC - HEALTH CANADA HAS ISSUED NOTICE OF COMPLIANCE WITH CONDITIONS FOR LARTRUVO\n* ELI LILLY CANADA - CONFIRMATORY PHASE 3 TRIAL IS CURRENTLY UNDERWAY TO FURTHER VERIFY CLINICAL BENEFIT OF OLARATUMAB Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-24T21:28:00.000+02:00",
    "crawled": "2018-01-25T13:16:54.031+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "eli",
        "lilly",
        "co",
        "lartruvo",
        "olaratumab",
        "approved",
        "canada",
        "treatment",
        "advanced",
        "soft",
        "tissue",
        "sarcoma",
        "adult",
        "eli",
        "lilly",
        "canada",
        "inc",
        "health",
        "canada",
        "issued",
        "notice",
        "compliance",
        "condition",
        "lartruvo",
        "eli",
        "lilly",
        "canada",
        "confirmatory",
        "phase",
        "trial",
        "currently",
        "underway",
        "verify",
        "clinical",
        "benefit",
        "olaratumab",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}